Thank you for your inquiry regarding CMS108: Venous Thromboembolism Prophylaxis (VTE-1). You can review all the value sets within the terminology section of the measure’s specifications, and plug the indicated OIDs to the VSAC ( https://vsac.nlm.nih.gov/ ) to review the qualifying terminology and medications for the measure. At this time, there is no approved indication to use Oral Factor Xa (Apixaban or Xarelto) for venous thromboembolism (VTE) prophylaxis with the exception of patients with history of either atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), or hip/knee replacement surgery. The measure specifications are consistent with the approved indications for Oral Factor Xa . If the FDA-approved indications should change in the future to include all hospitalized medical and surgical patients, then the measure specifications will be updated. Pradaxa (Dabigatran) is found in the value set "Direct Thrombin Inhibitor” RXNORM Value Set (2.16.840.1.113883.3.117.1.7.1.205) and is indicated in the logic under the low-risk indicator for VTE.